LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Allogene Therapeutics Inc

Închisă

SectorSănătate

1.34 -4.29

Rezumat

Modificarea prețului

24h

Curent

Minim

1.33

Maxim

1.35

Indicatori cheie

By Trading Economics

Venit

206K

-60M

EPS

-0.28

Marjă de profit

272,450

Angajați

226

EBITDA

-302K

-56M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+479.85% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

53M

308M

Deschiderea anterioară

5.63

Închiderea anterioară

1.34

Sentimentul știrilor

By Acuity

13%

87%

16 / 381 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Allogene Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 iun. 2025, 22:33 UTC

Achiziții, Fuziuni, Preluări

Millicom to Acquire Telefonica Ecuador for $380 Million

14 iun. 2025, 01:24 UTC

Achiziții, Fuziuni, Preluări

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13 iun. 2025, 23:50 UTC

Achiziții, Fuziuni, Preluări

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 iun. 2025, 23:20 UTC

Achiziții, Fuziuni, Preluări

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 iun. 2025, 23:09 UTC

Achiziții, Fuziuni, Preluări

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 iun. 2025, 23:03 UTC

Achiziții, Fuziuni, Preluări

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 iun. 2025, 22:18 UTC

Achiziții, Fuziuni, Preluări

Millicom to Acquire Telefonica Ecuador for $380M

13 iun. 2025, 22:04 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 iun. 2025, 21:42 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 iun. 2025, 21:35 UTC

Achiziții, Fuziuni, Preluări

Bunge: Outside Date Extended to July 3

13 iun. 2025, 21:35 UTC

Achiziții, Fuziuni, Preluări

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 iun. 2025, 21:34 UTC

Achiziții, Fuziuni, Preluări

Bunge Gets Mexico Approval for Viterra Deal

13 iun. 2025, 21:32 UTC

Achiziții, Fuziuni, Preluări

Bunge Gets China Approval for Viterra Deal

13 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 iun. 2025, 20:45 UTC

Achiziții, Fuziuni, Preluări

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 iun. 2025, 20:34 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 iun. 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 iun. 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 iun. 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 iun. 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

13 iun. 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

13 iun. 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 iun. 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

13 iun. 2025, 17:02 UTC

Achiziții, Fuziuni, Preluări

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 iun. 2025, 17:02 UTC

Achiziții, Fuziuni, Preluări

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 iun. 2025, 17:02 UTC

Achiziții, Fuziuni, Preluări

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 iun. 2025, 17:02 UTC

Achiziții, Fuziuni, Preluări

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

Comparație

Modificare preț

Allogene Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

479.85% sus

Prognoză pe 12 luni

Medie 7.77 USD  479.85%

Maxim 14 USD

Minim 2.5 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAllogene Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

11

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.18 / 1.69Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

16 / 381 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.